BioSpace News Archive

TScan Therapeutics, Inc. announced a poster presentation on the clinical trial design and trial in progress for the Phase 1 umbrella trial of TSC-100 and TSC-101 to treat residual leukemia and prevent relapse after hematopoietic cell transplantation at the 64th American Society of Hematology Annual Meeting 2022.

Pasithea Therapeutics Corp. today announced that it has reached a comprehensive Settlement and Cooperation Agreement (“the Agreement”) with Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Leonite Fund I, LP, Camac Partners, LLC, Camac Capital, LLC, Camac Fund, LP, David Delaney, Avi Geller, and Eric Shahinian (collectively, the “Camac Group”) resolving all outstanding issues between the parties.

PolyPid Ltd. today announced that a Type D meeting has been scheduled for January 2023 with the U.S. Food and Drug Administration (FDA) to discuss the results of SHIELD I Phase 3 study and regulatory requirements to support the indication of D-PLEX100 for the prevention of abdominal colorectal surgical site infections (SSIs).

Bausch + Lomb Corporation today announced its first-of-its-kind ONE by ONE and Biotrue Eye Care Recycling programs have been named a gold winner in the Most Environmentally Friendly Service of the Year category by the 2022 Best in Biz Awards.

Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of results and presentation of new research from its multiple myeloma portfolio across targets and molecular approaches at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring the company’s commitment to raising standards to transform multiple myeloma outcomes for every patient.

Schrödinger , Inc. today announced new preclinical data on its potent and selective CDC7 inhibitor, SGR-2921, in a poster session at the American Society of Hematology (ASH) 64th Annual Meeting taking place virtually and in New Orleans, Louisiana.

GlycoMimetics, Inc. today announced results from two investigator-sponsored trials studying uproleselan in patients with acute myeloid leukemia (AML).

Lumos Pharma, Inc. hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6th to review the Company’s interim data from two Phase 2 trials evaluating oral LUM-201 in moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD).

Genomic Biopharma Inc. has partnered with Associazione Poic e Dintorni APS to enable access to whole genome sequencing (WGS) and demonstrate the utility of genomic information to treat and cure the most severe disorders of gut motility.

Today, Quest Diagnostics (NYSE: DGX) released its latest Health Trends ® report, “Drug Misuse in America 2022: A Decade Lost to the Drug Crisis.”